The SEC under Paul Atkins’ leadership is working to remove rules deemed as “unnecessary” and reduce the Commission’s intervention in the industry, according to the Chair’s statement around the ...
With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...
Nuclear start-up Oklo has taken another step toward commercializing its technology, clearing a key regulatory hurdle for its coming Aurora powerhouse at Idaho National Laboratory.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results